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As the prevalence of cannabis use increases, it is clear that advanced practice registered 
nurses (APRN) will be caring for patients who either use cannabis to treat a qualifying 
condition or use it recreationally. Current curriculum lacks cannabis-specific knowledge 
necessary for APRNs to provide safe and appropriate care to patients using cannabis. The 
purpose of this project was to evaluate the impact of a teaching module intended to 
provide essential knowledge and clinical implications of medical cannabis for the APRN 
student. An educational module was developed based on The National Council of State 
Boards of Nursing (NCSBN) National Nursing Guidelines for Medical Marijuana 
Education in APRN Nursing Programs. A pre- and post-video survey consisting of nine 
knowledge items and one additional perceived importance question was developed and 
the project was reviewed by the Rhode Island College IRB as a quality improvement 
project. Rhode Island College APRN students were asked to participate by completing 
the pre-video survey, watching the educational video, and completing the post-video 
survey. A total of 24 students completed the pre-video survey and 19 students completed 
the post-video survey. The mean knowledge scores prior to the educational video ranged 
from “very poor” to “undecided” and improved to “somewhat good” to “very good” 
following the video. All participants perceived the importance of integrating cannabis 
education into the APRN curriculum as “moderately” or “extremely” important on both 
pre- and post-video surveys. Nursing regulatory organizations, together with accredited 
academic institutions, must evaluate current gaps in curriculum and work towards 
integrating cannabis-specific content. APRN students must have essential knowledge and 
clinical implications of medical cannabis in order to provide safe and appropriate care to 
patients using cannabis.   
 
 
Table of Contents 
 
Background/Statement of the Problem  .................................................................................. 1 
Literature Review ..................................................................................................................... 3 
Theoretical Framework.......................................................................................................... 30 
Method .................................................................................................................................... 32 
Results..................................................................................................................................... 40 
Summary and Conclusions .................................................................................................... 45 
Recommendations and Implications for Advanced Nursing Practice ................................ 49 
References .............................................................................................................................. 52 
Appendix A  ........................................................................................................................... 58 
















Development of an Educational Module related to Medical Marijuana for  
Advanced Practice Registered Nurse Curriculum 
Background/Statement of the Problem 
Marijuana, also known as cannabis, has been present in our society throughout 
history with varying levels of acceptance and legality (Bridgeman & Abazia, 2017). 
Public support for cannabis use over the past 10 years or so has led to a significant 
increase in its use. As of March 2020, 33 states, District of Columbia, Guam, Puerto 
Rico, and the U.S. Virgin Islands have approved medical marijuana/cannabis programs 
for patients with certification of a qualifying condition, while 14 states and territories 
have approved marijuana for adult recreational use (National Conference of State 
Legislatures (NCSL), 2020). 
Due to rapid change in societal attitudes towards cannabis and its increasing use, 
nurses and advanced practice registered nurses (APRNs) will undoubtedly be caring for 
patients who either use cannabis to treat a qualifying condition or use it recreationally. As 
cannabis has been classified as a Schedule I Controlled Substance following the Federal 
Comprehensive Drug Abuse Prevention and Control Act of 1970, research on efficacy, 
indications, and long-term effects has been limited and lacking. Pre-licensure and APRN 
curriculum have subsequently lacked instruction related to the pharmacology, physiologic 
effects, uses, neurological symptoms, drug-to-drug interactions, and adverse effects of 
cannabis.  
In order to better ensure that APRNs provide safe and appropriate patient care, 
cannabis-specific curriculum content is necessary. Curriculum must not only provide 
knowledge related to the current state of legalization and research, but also the 
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endocannabinoid system, pharmacology, and most importantly, safety considerations for 
the patient using cannabis. The purpose of this project is to evaluate the impact of a 
teaching module intended to provide essential knowledge and clinical implications of 
medical cannabis for the APRN student.  






The Cannabis Plant and Historical Use 
 Cannabis is a generic term used to describe plants belonging to the genus 
Cannabis sativa, Cannabis indica, and Cannabis ruderalis. The 1961 United Nations 
Single Convention on Narcotic Drugs more specifically defined cannabis as “the 
flowering or fruiting tops of the cannabis plant from which resin has not been extracted” 
(Madras, 2015, p. 3). With origins dating back more than 5,000 years, cannabis had been 
widely used as a patent medication in the United States during the 19th and early 20th 
centuries. Cannabis was described in the 3rd edition of the U.S. Pharmacopoeia (U.S.P.) 
for the first time in 1850 under the name of Extractum Cannabis or Extract of Hemp. 
More than 20 prescription medications containing cannabis were sold at U.S. pharmacies 
between 1850 and 1937 and U.S. medical practices used these medications to treat a wide 
range of ailments (Bridgeman & Abazia, 2017). 
Regulation of cannabis and increased restrictions began around 1906 after which 
prohibitions and state-by-state regulations eventually led to the passage of the Marihuana 
Tax Act of 1937. Cannabis was dropped from the U.S.P. in 1942 and as a result, legal 
penalties for possession of cannabis continued to increase throughout the 1950s. The 
passage of the U.S. Drug Enforcement Agency’s (DEA) Comprehensive Drug Abuse 
Prevention and Control Act of 1970 officially outlawed cannabis for any use (including 




As a Schedule I Controlled Substance, the cannabis plant has been defined as 
“having high potential for abuse, no currently accepted medicinal use in treatment in the 
United States, and a lack of accepted safety data for use of the treatment under medical 
supervision” (Bridgeman & Abazia, 2017, p. 180). The plant contains at least 750 
chemicals including over 104 different cannabinoids including dronabinol, also known at 
9-tetrahydrocannabinol, or THC, cannabidiol (CBD), and cannabinol (CBN). 
Tetrahydrocannabinol (THC) is the primary psychoactive compound, while CBD is the 
non-psychoactive compound. Despite criminalization and legislative actions limiting use, 
research, and distribution, cannabis has continued to be the most cultivated, trafficked, 
and abused illicit drug worldwide (Madras, 2015).  
Recent efforts to revive cannabis as a medicine have been driven by multiple 
factors, with the most prominent being the inability of current medical approaches and 
pharmaceuticals to provide symptom relieve to individuals suffering from debilitating 
chronic disease. Current cannabis consumption has reached an all-time high, with an 
annual prevalence rate of approximately 147 million individuals, or nearly 2.5% of the 
global population (Madras, 2015). The 2016 National Survey on Drug Use and Health 
results estimated 24.0 million Americans aged 12 years of age or older reported current 
cannabis use with 8.9 percent of the population aged 12 years or older reported use within 
the previous month. Not only has the percentage of people aged 12 years or older 
reporting current cannabis has increased from 2002 to 2015, but the increase in use 
among this younger age group is also greater than the increase in use reported by adult 
age groups 18 to 25, and 26 or older. (Substance Abuse and Mental Health Services 
Administration, 2017)  
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Prevalence reports consistently demonstrate that cannabis use for both 
recreational and medicinal purposes continues to rise (Madras, 2015), while legislative 
actions, ballot measures, and public opinion polls also reflect increased societal 
acceptance of cannabis use, especially for medical purposes. For example, the 2016 
Gallup poll on American’s views on legalizing cannabis indicated that 60% of the 
population surveyed believed cannabis should be legalized. Despite continued 
controversies surrounding the legal, ethical, and social implications of cannabis, as of 
March 2020, 33 states, District of Columbia, Guam, Puerto Rico, and the U.S. Virgin 
Island have approved medical use and 14 states have approved the use of cannabis 
recreationally (NCSL, 2020).  
Federal and State Legislation through 2019 
 Classification of cannabis as a Schedule I Controlled Substance both prohibits 
practitioners from prescribing cannabis and also prohibits research using cannabis, except 
for federally funded research under the oversight of the National Institute on Drug Abuse 
(U.S. Food and Drug Administration [FDA], 2019). Despite Drug Enforcement 
Administration (DEA) classification and federal law, individual states have instituted 
varying legal approaches to authorizing medical marijuana programs over the past few 
decades, with more recent efforts focusing on introducing federal bills in an effort to 
reschedule cannabis. In 2016, the Food and Drug Administration (FDA) requested a 
scientific and medical evaluation and scheduling recommendation from the Department 
of Health and Human Services (HHS). The report and recommendations concluded that 
marijuana has a high potential for abuse, has no currently accepted medical use in 
treatment in the United States, and lacks accepted safety for use under medical 
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supervision (Drug Enforcement Administration [DEA], 2016); thus, the DEA denied 
petitions to reschedule cannabis as a Schedule II Controlled Substance. The DEA did, 
however, recognize the lack of scientific study on cannabis and announced a policy 
change which expanded the number of DEA-registered cannabis manufacturers to 
increase the supply of cannabis for FDA-authorized research. (The National Council of 
State Boards of Nursing [NCSBN], 2018) 
 In terms of state legislation, each jurisdiction’s medical marijuana program, or 
MMP, is unique, with state-specific statues in place which differ in provisions regarding 
the process for procuring a certification for the use of cannabis, the amount of cannabis 
that can be distributed to an individual, legal protections, designation of caregivers, and 
health care provider responsibility. Medical marijuana programs also have differing 
qualifying conditions/diagnoses, disease states, or symptoms that enable a patient to 
obtain certification and register with the state as a medical marijuana patient. (NCSBN, 
2018) There are 57 qualifying conditions included among the different jurisdictional 
laws, with the most common being: ALS; Alzheimer’s disease; arthritis; cachexia; 
cancer; Chron’s disease and other irritable bowel syndromes; epilepsy or seizure 
disorder; glaucoma; hepatitis C; HIV/AIDS; nausea; neuropathies; pain; Parkinson’s 
disease; persistent muscle spasms (including multiple sclerosis); post-traumatic stress 
disorder; sickle cell disease; and terminal illness (Madras, 2015; NCSBN, 2018). 
            The National Conference of State Legislatures (NCSL, 2020) provides useful 
state-specific medical marijuana resources and guidelines for practitioners to become 
knowledgeable of their role. For example, as federal law prohibits practitioners from 
prescribing cannabis, some MMPs require an established and ongoing health care 
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provider-patient relationship in order to certify, while others require just a consultation 
and written recommendation. A few MMPs allow advanced practice registered nurses 
(APRNs) to certify, but most only allow medical doctors (MDs), with some MMP 
programs requiring practitioners to undergo specific training in order to be a participating 
provider. Medical marijuana programs also have provisions for hospice providers, 
nursing, medical facilities, personal care attendants, or home health aides to act as a 
designated caregiver for the administration of medical marijuana to ill patients (NCSBN, 
2018; NCSL, 2020). 
Use of Cannabis for Medical Purposes 
 Currently, the U.S. FDA does not approve the application of the cannabis plant 
for the treatment of any disease or condition; however, one cannabis-derived and three 
cannabis-related drug products have been approved and are available with a prescription 
from a licensed healthcare provider. Epidiolex, which contains a purified form of CBD 
has been approved for the treatment of seizures, while Marinol and Syndros, which 
include the psychoactive ingredient THC, have been approved for use as an anti-emetic, 
appetite stimulant, multiple sclerosis treatment, and for spasticity, respectively. Cesamet, 
approved to treat severe nausea and vomiting caused by cancer drug treatment, contains 
the active ingredient nabilone, which is a synthetic chemical similar to THC. (Medscape, 
2006; FDA, 2019). 
 Whiting and colleagues (2015) defined medical cannabis as the use of the 
unprocessed cannabis plant, not a prescription pharmaceutical, for medical therapy to 
treat disease or alleviate symptoms. In order to use cannabis for medical purposes, MMPs 
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have established conditions which qualify a patient to use cannabis (NCSBN, 2018). 
However, the NCSBN (2018) review revealed that such conditions have generally been 
included based on limited availability of clinical research, or because of symptoms they 
share with conditions better studied in the literature. For example, the more general 
qualifying conditions such as chronic pain, neuropathies, and nausea are the most 
researched symptoms associated with medical cannabis. Although research comparing 
the effects of cannabis against other standard medications do exist, clinical trials are 
small in number, with varying risk of bias. As a result, research has not been able to 
definitively specify indications, dosage, route, safety, adverse effects, and long-term 
effects of cannabis, let alone clinical guidelines for practitioners (NCSBN, 2018). 
 The most prominent and thorough reports and review of the medical cannabis 
literature have been conducted by the World Health Organization (WHO) (Madras, 
2015), Whiting and colleagues (2015), and The National Academy of Sciences (2017). 
The WHO report does not provide a comprehensive review of the literature, but rather 
summarizes evidence of cannabis for medicinal use globally, citing sources from primary 
manuscripts and 10 meta-analyses. It highlights therapeutic indications and 
considerations for neurological diseases and symptoms, AIDS wasting, cachexia and 
appetite enhancement, cancer and cancer-related symptom management, Crohn’s disease, 
Post-traumatic stress disorder (PTSD), and glaucoma (Madras, 2015).   
 The WHO report used an international survey by Hazekamp, Ware, Muller-Vahl, 
Abrams, and Grotenhermen (2013) to demonstrate the global use of medical cannabis. 
Respondents (n = 953) from the United States, Germany, Canada, France, the 
Netherlands, and Spain were self-reported users of cannabis for medicinal purposes, 
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generally male (64%), and the mean age was 40.7. This population reported using 
cannabis for back pain (11.9%), sleeping disorders (6.9%), depression (6.7%), injury or 
accident-generated pain (6.2%), and multiple sclerosis (4.1%). 
Whiting et al. (2015) published the highly regarded medical cannabis resource 
following a systematic review to determine the benefits and adverse events (AEs) of 
cannabis. A total of 79 randomized clinical trials (6,462 participants) comparing cannabis 
with usual care, placebo, or no treatment for the following indications were included: 
nausea and vomiting due to chemotherapy; appetite stimulation in HIV/AIDS; chronic 
pain; spasticity due to multiple sclerosis or paraplegia; depression; anxiety disorder; sleep 
disorder; psychosis; glaucoma; or Tourette’s syndrome. The main outcomes and 
measures were patient-relevant and disease-specific outcomes, activities of daily living, 
quality of life, global impression of change, and AEs. Common AEs reported included 
dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, 
drowsiness, confusion, loss of balance, and hallucination. Study quality was assessed 
using the Cochrane risk of bias tool, all review stages were conducted independently by 
two reviewers, and data were pooled using random-effects meta-analysis. 
 Four trials (5%) were judged at low risk of bias, 55 (70%) high risk, and 20 (25%) 
unclear risk; however, the major source of bias was determined to be incomplete outcome 
data, with more than 50 percent of trials reporting unacceptably high drop-out rates 
among cannabis-naïve subjects. Results demonstrated that most trials showed 
improvement in symptoms associated with cannabis use; however, the associations did 
not reach statistical significance in all trials. Compared with placebo, cannabis was 
associated with a greater average number of patients showing a complete nausea and 
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vomiting response (47% vs. 20%; odds ratio 3.82 [95% Cl, 1.55-9.42]; 3 trials), reduction 
in pain (37% vs. 31%; odds ratio 1.41 [95% Cl, 0.99-2.00]; 8 trials), a greater average 
reduction in numerical rating scale pain assessment (on a 1-10-point scale; weighted 
mean difference -0.46 [95% Cl, -0.08 to -0.11]; 6 trials), and average reduction in the 
Ashworth spasticity scale (weighted mean difference -0.12 [95% Ci, -0.24 to 0.01]; 5 
trials). Studies found an increased risk of short-term AEs with cannabis use, including 
dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, 
drowsiness, confusion, loss of balance, and hallucination (Whiting et al., 2015).  Whiting 
et al. concluded that moderate-quality evidence existed supporting the use of cannabis for 
the treatment of chronic pain and spasticity while low-quality evidence suggested that 
cannabis was associated with improvements in nausea and vomiting due to 
chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. 
 In the National Academies of Sciences, Engineering, and Medicine 2017 report, 
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and 
Recommendations for Research, experts developed a standard language to categorize the 
weight of the evidence for cannabis used medicinally for specific health conditions. 
“Conclusive” evidence existed when strong evidence from randomized controlled trials, 
and/or many good-quality studies supported the conclusion that cannabis was an effective 
or ineffective treatment for the health condition. “Substantial” evidence existed when 
several supportive good-quality studies existed with very few or no credible opposing 
findings. “Moderate” evidence referred to the existence of “some” evidence but with 
identified limitations, such as chance, bias, and confounding factors, that could not be 
ruled out with reasonable confidence. “Limited” evidence was determined when there 
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were supportive findings from fair-quality studies or mixed findings; a significant amount 
of uncertainty existed. Finally, “insufficient” evidence was reported when there were 
mixed findings, a single poor study, or no studies at all. (National Academies, 2017) 
 Conclusive or substantial evidence was determined for therapeutic use of cannabis 
for the treatment of chronic pain, as an antiemetic in the treatment of chemotherapy-
induced nausea and vomiting, and in the improvement of patient-reported multiple 
sclerosis spasticity symptoms. (National Academies, 2017) Moderate evidence supported 
cannabis being effective for improving short-term sleep outcomes in individuals with 
sleep disturbances associated with obstructive sleep apnea syndrome, fibromyalgia, 
chronic pain, and multiple sclerosis (NCSBN, 2018). A greater amount of substantial 
evidence suggested adverse outcomes of cannabis such as the statistical association 
between cannabis smoking and worse respiratory symptoms, more frequent bronchitis, 
increased risk of motor vehicle crashes, lower birth weight of offspring, development of 
schizophrenia or other psychoses, and development of problematic cannabis use 
(National Academies, 2017).  
 A review of the literature searching all scholarly articles related to cannabis and 
its’ derivatives and the qualifying conditions listed by jurisdiction through February of 
2018 was completed by the NCSBN to inform the establishment of the National Nursing 
Guidelines for Medical Marijuana published in July 2018. Their review highlighted 
evidence that cannabinoids underperformed against standard first-lime medical 
treatments for pain, nausea, and cachexia, namely megestrol acetate, ondansetron, and 
dihydrocodeine respectively and showed effects comparable to tramadol and pregabalin.  
Cannabis was shown to carry its’ own set of AEs, with one risk being that patients may 
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forego effective standard medications in favor of cannabis. The review validated the 
moderate- to high-quality evidence supporting cannabis as an effective treatment for 
cachexia, chemotherapy-induced nausea and vomiting, pain, chronic pain, neuropathies, 
spasticity, reduction in seizure frequency, reduction in PTSD nightmares, and 
improvement in ticks. Other research by Fox et al. and Greenberg et al., both cited in 
NCSBN (2018), posited, however, that improvements in other symptomatology might be 
related to the more general effects of cannabis, including sedation, appetite stimulation 
and euphoria, which mask symptoms and increase a subjective sense of well-being 
leading to improved self-reported quality of life in study participants (NCSBN, 2018). 
Physiologic, Therapeutic, and Adverse Effects of Cannabis 
The endocannabinoid system. Although the cannabinoid signaling system is 
ancient, existing in invertebrates and advanced vertebrate organisms (Madras, 2015), the 
discovery of how cannabis interacts with the body has been a slow one. The brain’s 
opiate receptor was identified in 1973, but it wasn’t until 1988 that a government-funded 
study by Allyn Howlett and William Devane determined not only that the mammalian 
brain has receptor sites that respond to compounds found in cannabis, but also that these 
receptors are the most abundant type of neurotransmitter receptor in the brain (Moore, 
2018).  
 Over the last 25 years, the endocannabinoid system (ECS) has emerged as an 
important neuromodulatory system that plays an important role in central nervous system 
(CNS) development, synaptic plasticity, and the response to endogenous and 
environmental insults (Lu & Mackie, 2016). The ECS has four main components: G 
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protein-coupled cannabinoid CB1 and CB2 receptors; endogenous endocannabinoids, or 
lipids, produced by the body which target these receptors (five endocannabinoids have 
been identified as compared to over 100 detected in the cannabis plant (Grotenhermen, 
2004); enzymes that catalyze or break down endocannabinoids for use by the body; and 
mechanisms involved in synaptic and cell messaging (Lu & Mackie, 2016; Madras, 
2015).  
 Function of the endocannabinoid system. Endocannabinoids play a 
fundamental role in regulating pleasure, memory, thinking, concentration, body 
movement, awareness of time, appetite, pain, sensory processing, and brain development 
(Madras, 2015). In the brain and CNS, endocannabinoid signaling controls excitatory and 
inhibitory synaptic transmission and regulatory functions in the brain through many 
intricate mechanisms. This signaling guides neural stem cell survival and proliferation, 
modulates the extent of brain damage resulting from mechanical, blood flow, or other 
forms of injury, and coordinates sensory input, which in turn regulates neurogenesis, 
appetite, nausea, sleep, neurotransmitters, seizure activity, motor function, and cognitive 
function (Kumar, Chambers, & Pertwee, 2001; Madras, 2015). 
 In peripheral tissues, endocannabinoid signaling accounts for effects throughout 
the intestinal mucosa such as inhibition of gastrointestinal motility and gastric emptying. 
Increased cardiac output, myocardial oxygen requirement, and tachycardia commonly 
result from endocannabinoid activation inhibiting the vagal nerve (Grotenhermen, 2004). 
Other peripheral effects of cannabinoids include increased liver cell metabolism; 
increased activity of immune cells; increased energy metabolism in muscle cells and the 
formation of new muscle fibers; regulation of critical stages of pregnancy and the 
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preservation of normal sperm function; and perhaps respiratory urinary system function 
(Kumar et al., 2001; Madras, 2015). 
 Pharmacology. The effects of endocannabinoids are primarily mediated by CB1 
and CB2 receptors. CB1 receptors are abundant in the CNS, particularly on axon and pre-
terminal axon segments in the cerebellum, hippocampus, cortex, and basal ganglia. 
Activation of these CNS receptors is responsible for the effects of cannabinoids on 
cognition, coordination, learning and memory, cognitive function, executive function and 
control, integration of sensory input, motor control, and planning (Lu & Mackie, 2016; 
Madras, 2015). CB1 receptors have also been found in the central striatum responsible 
for prediction and the feeling of reward, the amygdala responsible for feelings of anxiety, 
emotion, and fear, the hypothalamus controlling appetite, hormone levels, and sexual 
behavior, and the brain stem and spinal cord which control vomiting and pain perception. 
CB2 receptors are expressed at much lower levels in the CNS and are primarily present in 
microglia which are the macrophages that act as the primary immune system of the brain 
and spinal cord. These receptors are also found in vascular tissue, on immune cells, and 
within the hematopoietic system which consists of bone marrow, spleen, thymus and 
lymph nodes. (Lu & Mackie, 2016; Madras, 2015) In addition to CB1 and CB2 receptors, 
several other receptor subtypes have been reported to interact with cannabinoids (Zou & 
Kumar, 2018).    
 The mechanism of action of cannabinoids has been established mainly based on 
THC’s agonistic action at the cannabinoid receptors (Grotenhermen, 2004). Increased 
interest in cannabidiol (CBD) and its’ unique therapeutic uses has led to ongoing 
investigation into its mechanism of action. Unlike THC, CBD does not activate CB1 and 
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CB2 receptors, which accounts for its lack of psychotropic activity. Cannabidiol has been 
found to potentiate some of THC’s beneficial effects as it reduces THC’s psychoactivity, 
thus allowing patients to tolerate higher, more therapeutic doses of THC. Besides its 
effect on THC, CBD has been called a “multi-target” drug as it interacts with numerous 
other non-endocannabinoid signaling system receptors such as G-protein-coupled 
receptors, 5-HT1a receptor, and alpha 3 and alpha 1 glycine receptors for example. 
CBD’s activation of multiple targets contributes to its many properties ranging from 
analgesic, anti-inflammatory, antioxidant, anti-spasmodic, and anti-epileptic. (Devinsky 
et al., 2014)  
 Pharmacokinetics. The pharmacokinetics of cannabis, or the absorption, 
distribution, metabolism, and elimination of any drug is highly variable based on the 
route of administration. Inhaled drugs enter the lungs and cross into the bloodstream at a 
rate similar to if the drug was injected intravenously. Drugs taken orally, however, are 
absorbed mainly through the small intestine but are subject to liver metabolism and 
gastrointestinal (GI) variables such as drug-food interaction, drug-drug interaction, and 
GI health (Whalen, 2019). The three most common methods of cannabis administration 
are inhalation via smoking, inhalation via vaporization, and ingestion of edible products 
(Bridgeman & Abazia, 2017). Cannabis comes in other forms such as pills, oil, topical 
ointments and creams, liquid drinks, and suppositories.  Method of administration 
impacts the onset, intensity, duration of effect, as well as the effect on organ systems, 
addictive potential and negative consequences associated with use (Bridgeman & Abazia, 
2017; Madras, 2015). Thus, cannabinoid pharmacokinetic research has been challenging.  
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 Tetrahydrocannabinol and other cannabinoids are rapidly absorbed after 
inhalation or intravenous administration with maximum brain concentration being 
reached within 15 minutes (Bridgeman & Abazia, 2017). Maximum psychological and 
physiological effects reach a plateau lasting two to four hours before slowly declining. 
The amount absorbed varies between 20 and 45% of the THC content. When taken 
orally, THC undergoes variable absorption depending on GI variables and has been 
shown to have a narrower therapeutic window. Blood concentrations following oral 
consumption have been shown to reach only 25-30% of those obtained by smoking the 
same dose. Due to GI variables, onset of effect is also delayed 30 minutes to 2 hours 
following oral consumption, with the duration of effect lasting five to six hours and 
psychomotor and cognitive effects persisting much longer. is prolonged due to slow 
absorption from the gut. (Bridgeman & Abazia, 2017) Cannabinoids do cross the 
placenta, enter fetal circulation, penetrate breast milk, and accumulate in fatty tissues and 
thus elimination from the body is very slow. Cannabinoids are metabolized by the liver, 
contributing to large individual differences in rates of metabolism. (Bridgeman, 2017; 
Kumar et al., 2001) 
 Adverse effects and safety considerations. The effects of cannabinoid 
consumption are euphoria and relaxation, perceptual alteration, time distortion and the 
intensification of normal sensory experiences. Short-term memory and attention, motor 
skills, reaction time and skilled activities are impaired with impairments being dose-
dependent and potentiated with concomitant alcohol intake. Anxiety and panic reaction 
are common and effects on the cardiovascular system include tachycardia with heart rate 
increases of 20-50% within a few minutes lasting for up to 3 hours. Blood pressure tends 
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to decrease when standing but not when sitting (Bridgeman & Abazia, 2017; Kumar et 
al., 2001). The lethal dose of oral THC has been established in rats; however, no cases of 
death due to toxicity following the maximum oral THC dose in dogs and monkeys 
occurred (Grotenhermen, 2004). Acute fatal cases in humans have not been substantiated 
to-date and long-term, large sample size studies have failed to show an increase in 
cardiovascular mortality related to cannabis use (Frost, Mostofsky, Rosenbloom, 
Mukamal, & Mittleman, 2013; Mukamal, Maclure, Muller, & Mittleman, 2008; Sidney, 
Beck, Tekawa, Quesenberry, & Friedman, 1997). As THC is known to cause tachycardia 
and increased cardiac output, its use may be associated with increased mortality in 
patients with a history of myocardial infarction or increased risk of precipitating an acute 
coronary event in susceptible patients (Kattoor & Mehta, 2016) 
Isolated cannabinoids have undergone a number of randomized controlled trials 
(RCTs) documenting safety, efficacy, and side effect profiles in order to formalize the 
drug approval process for the three current pharmaceuticals including Marinol, Syndros, 
and Epidiolex (FDA, 2019). Few RCTs are reported for whole plant cannabis and the 
majority of trials have several limitations so the safety of cannabis cannot be assured at 
this time without key information. (Madras, 2015; National Institute on Drug Abuse 
[NIDA], 2019; Whiting et al., 2015) 
 A systematic review by Wang, Collet, Shapiro, and Ware (2008) evaluated a total 
of 31 studies (N=3,122) including 23 RCTs examining the use of medical cannabinoids 
and AEs. A total of 4,779 AEs were reported; 96.6% or 4,615 were not deemed by the 
authors to be serious. The most common serious AEs included relapsing MS (9.1%; 15 
events), vomiting (9.8%; 16 events), and urinary tract infections (9.1%; 15 events). 
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Interestingly, no significant differences in the rates of serious adverse events between 
individuals receiving medical cannabis and controls were identified (relative risk, 1.04; 
95% CI, 0.78-1.39). The most commonly reported non-serious adverse event was 
dizziness, with an occurrence rate of 15.5% (714 events). Other negative adverse effects 
reported with acute cannabis use included hyperemesis syndrome, impaired coordination 
and performance, anxiety, suicidal ideations or tendencies, and psychotic symptoms.  
Chronic effects included mood disturbances, exacerbation of psychotic disorders, 
cannabis use disorders, withdrawal syndrome, and neurocognitive impairments, as well 
as cardiovascular and respiratory conditions (Wang et al., 2008).  
 Drug interactions may exist between cannabis and other pharmaceuticals 
especially since  hepatic cytochrome 450 (CYP 450) isoenzymes 2C9 and 3A4 play a 
significant role in the primary metabolism of THC and CBDA, whereas 2C19 and 3A4 
may be responsible for metabolism of CBD. Limited clinical trials have sought to 
quantify this effect, but drug information data available on the two current cannabinoid 
pharmaceuticals--Marinol and Syndros--reported altered THC and CBD levels with 
concomitant administration of ketoconazole and rifampin. Additionally, smoking 
cannabis may increase theophylline metabolism as is also seen after smoking tobacco 
(Bridgeman & Abazia, 2017). 
Cannabis and central nervous system impairment. The growing use of cannabis 
worldwide has led to more recent increases in the number of human studies, especially 
related to concerns of harmful effects. Neuroimaging techniques are being used to 
determine the effects of cannabis on brain structure and function (Batalla et al., 2013). 
Cognitive functions such as attention, concentration, decision-making, impulse control, 
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reaction time, verbal fluency, and working memory had previously demonstrated 
inconsistent acute impairment in a dose-dependent manner (Crean, Crane, & Mason, 
2011). Several cognitive functions had also been shown to be impaired in recently 
abstinent cannabis users for seven hours up to 20 days. Following sustained abstinence in 
chronic, daily cannabis users, impairment in cognitive functioning continued for several 
months with decision-making, planning, and concept formation being the most prominent 
and durable deficits (Madras, 2015; Wadsworth, Moss, Simpson, and Smith, 2006).  
A recent literature review by Mandelbaum and Monte (2017) reported the 
existence of “strong evidence” that chronic cannabis abuse causes cognitive impairment 
and physical damage to the brain, particularly white matter, theorized to be due to the 
high saturation of CB1 receptors in that area. Similarly, Nader and Sanchez (2018) 
systematically reviewed 13 neuropsychological studies addressing a variety of cognitive 
domains, 25 structural neuroimaging studies, and 18 functional neuroimaging studies 
comparing a group of regular cannabis users with a group of controls consisting of non-
users or individuals with very limited drug experience. Important findings confirmed the 
most frequently affected cognitive domains to be executive functioning, memory, 
attention, and learning. Evidence existed among thirteen studies reviewed that cognitive 
impairment is reversible with scores on neuropsychological test battery (Halstead-Reitan 
Battery) administered to cannabis users and control group demonstrating “virtually no 
differences between the groups” (Nader & Sanchez, 2018, pg. 11). However other studies 
such as one conducted by Meier et al. (2012) showed that those who initiating cannabis 




Nader and Sanchez’s (2018) systematic review of 22 structural neuroimaging 
studies also confirmed the link between brain structure and connectivity. Findings 
determined that whole brain volume was not affected by cannabis use, but that CB1-rich 
areas such as the amygdala and hippocampus showed structural alterations. Functional 
neuroimaging studies also revealed altered patterns of brain activities in cannabis users, 
possibly due to upregulation of CB1 receptors. They concluded that the implications of 
the structural and functional findings as a result of cannabis use are yet to be determined, 
but added that even small impairment in cognitive functioning should be concerning.	
 
Harmful effects to peripheral tissues. Chronic cannabis use has been associated 
with an increased prevalence of symptoms of chronic bronchitis, inflammation to central 
airways, and increased rates of respiratory infections and pneumonia comparable to that 
of smokers of tobacco. Cannabis use has not been associated with adverse effects on 
pulmonary function testing nor does it appear to contribute to chronic obstructive 
pulmonary disease nor are its’ carcinogenic effects clear at the present times. Use has 
been associated with increased risk of myocardial infarction (MI), stroke, and transient 
ischemic attaches (TIA) during cannabis intoxication (Madras, 2015). 
Carcinogenic potential. There is currently no consensus on whether cannabis use 
is associated with overall cancer risk; however, cannabis smoke contains several of the 
same carcinogens as tobacco smoke at up to 50% higher concentrations with three times 
the tar per cigarette. In vitro and in vivo evidence has demonstrated pre-neoplastic 
histological and molecular changes to respiratory mucosa exposed to chronic cannabis 
smoke (Madras, 2015).  A 2015 systematic review identified four cohort studies and 30 
case-control studies investigating cannabis use and cancer risk: 11 studies on upper 
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digestive cancers, six studies on lung cancer, three studies on testicular germ cell tumors, 
six studies on childhood cancers, one study on all cancers, one study on anal cancer, one 
study on penile cancer, two studies on non-Hodgkin lymphoma, one study on malignant 
primary gliomas, one study on bladder cancer, and one study on Kaposi sarcoma (Huang 
et al., 2015). The largest number of studies investigating the impact of cannabis and 
cancer involve head and neck cancer. Pooled analyses  reported no overall association for 
head and neck cancer but a possible increased risk with dose response for oropharyngeal 
cancer and a decreased risk for tongue cancers (Huang et al., 2015). Studies identifying 
dosage and use found that even “highest exposure categories” rarely exceeded 10 joint-
years of cumulative lifetime use which would translate into only 0.5 pack-years of 
cigarette smoking. Thus, the smaller amounts of cannabis that are regularly smoked 
compared with tobacco was suggested to explain the null association of cannabis with 
lung cancer. The authors also discussed the tumor-suppressant effect of THC and other 
cannabinoids which could possibly counteract the tumor-promoting effects of the 
carcinogens. For the other cancers, the review concluded that there was still insufficient 
data to make any conclusions whether an association existed between cancer and 
cannabis use (Huang et al., 2015). 
A more recent meta-analysis by Park and Myung (2018) also looked at lung 
cancer. The analysis which included a total of 13,646 cancer patients and 151,572 
participants without cancer. Results showed a marginally statistically significant 
association between cannabis smoking and risk of lung cancer (OR=1.76, 95% CI 1.00-
3.08). Subgroup analysis also showed an increase risk of testicular cancer when the 
duration of cannabis smoking exceeded 10 years (OR=1.50; 95% CI, 1.02-2.09). Thus, as 
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cannabis use rates continue to increase, well-designed, large-scale studies are necessary 
to best determine the potential risks conferred by its use (Huang et al., 2015).  
Cannabis during development. Accumulating evidence suggests that prenatal 
exposure may interfere with normal development and maturation of the brain as children 
exposed to cannabis in utero demonstrate impaired attention, learning, memory, 
impulsivity, behavioral problems, and higher likelihood of using cannabis when they 
mature (Sonon, Richardson, Cornelius, Kim, & Day, 2015). Regular, heavy cannabis use 
during adolescence has been associated with cognitive deficits, impaired attention, 
learning, memory, and IQ reduction. Brain imaging has also revealed changes in 
adolescents or adults who initiated cannabis during adolescence such as smaller whole 
brain and hippocampus, reduced cortical grey matter and insular cortical thickness 
associated with level of use. Findings have obvious implications for education and also 
have been associated with lower income level, lower college degree completion, greater 
need for economic assistance, unemployment, and use of other drugs. (Madras, 2015; 
Osuch et al., 2016).  
Cannabis and society. In addition to the above, cannabis use continues to present 
a widespread and serious personal and public health problem (Stinson, Ruan, Pickering, 
& Grant, 2016). As cannabis use rises, an increasing burden on emergency services 
documenting cannabis use alone or in combination with other drugs has increased. A 
nationwide study by Dr. He Zhu and Dr. Li-Tzy Wu (2016) of Duke University Medical 
Center showed that across the United States, between 2004 and 2011, emergency 
department visits involving the use of cannabis increased from 51 to 73 per 100,000 
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patients with those involving cannabis combined with other drugs also increased from 63 
to 100 per 100,000. 
Cannabis consumption impairs driving ability and confers a higher risk for motor 
vehicle accidents. The effects of cannabis on cognition also affect work, employment, 
performance, and everyday life, potentially increasing unemployment among users. 
Cannabis for medical use has recently created dilemmas for the workplace, as ensuring 
safety of workers who are under the influence or who recently consumed cannabis is not 
possible (Madras, 2015). 
Dependence, abuse, and cannabis use disorder (CUD). Classifying cannabis use in the 
U.S. is dictated by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) 
(2013). The World Health Organization’s (2019) International Statistical Classification 
of Diseases and Related Health Problems (11th ed.; ICD-11) and DSM-V have 
designated that cannabis is addictive and currently recognizes cannabis-related 
dependence disorders. Generally, the effects of cannabis use can be understood as acute 
and chronic. The acute phase includes intoxication and withdrawal states, along with 
secondary complications: delirium; psychosis; anxiety; and insomnia. Chronic regular use 
can be characterized by disordered behavior (APA, 2013; WHO, 2019). 
Depending on the setting (i.e., Emergency Department, office visit, or 
rehabilitation program), different effects of cannabis may be the focus and the diagnostic 
criteria of the varying effects can be defined as: cannabis intoxication; cannabis 
withdrawal; cannabis intoxication delirium; cannabis-induced psychotic disorder; 
cannabis-induced anxiety disorder; cannabis-induced sleep disorder (APA, 2013). 
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According to the latest World Drug Report published June of 2019 by the United 
Nations Office on Drugs and Crime (UNODC), approximately 35 million people are 
estimated to suffer from drug use disorders requiring treatment services. Approximately 
13.1 million people globally are psychologically or physiologically dependent on 
cannabis based on 2017 estimates by UNODC. Data from the US indicates that the 
prevalence of cannabis use increases when perceived risk of use decreases. Perception of 
risk has declined in the face of changing legal status of the drug, which researchers claim 
has resulted in the rise in daily use among youth (Miech, Johnston, & O’Malley, 2017). 
As a consequence of increased use, it comes as no surprise that the rate of reported CUD 
in the US has climbed significantly (Madras, 2015). 
Implications for Advanced Practice Nursing Education 
As the use of both medical and recreational cannabis continues to rise, the fields 
of public health, science, and education, as well as healthcare providers, must adjust to 
support the needs of the population. Advanced practice registered nurses (APRNs), 
including nurse practitioners, clinical nurse specialists, nurse anesthetists, and nurse 
midwives, play a pivotal role in the future of health care and are increasingly the primary 
care providers at the forefront of providing services to the public (ANA, 2018) .The 
landmark document Consensus Model for APRN Regulation: Licensure, Accreditation, 
Certification, and Education (NCSBN, 2008) delineates APRN roles and provides 
recommendations about APRN licensure, accreditation, certification, and education. 
According to the Consensus Model, APRNS must complete an accredited master’s or 
doctorate program.  
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APRN education. The American Nurses Association and Nurse Practice Acts 
outline that APRNs must have sufficient depth and breadth of clinical experience as RNs, 
and APRN education must build on their RN competencies. They must be prepared to 
assume responsibility for health promotion and maintenance as well as assessment, 
diagnosis, and management of patient problems, including the use and prescription of 
nonpharmacologic ad pharmacologic interventions (ANA, 2018). Current APRN 
programs require students to complete the “3 Ps”: advanced pharmacology; advanced 
pathophysiology; and advanced physical health assessment. These foundational courses 
require the maturation of foundational knowledge as well as the development of 
advanced critical-thinking skills. Advanced practice registered nurses must meet clinical 
competencies which are defined by patient-care needs, not practice setting, and must 
maintain national certification and practice with a significant focus on direct patient care 
(ANA, 2018). 
Knowledge gaps. As awareness of and interest in the use of medical cannabis has 
increased, it has become clear that health care professionals need to be involved in 
management decisions but often feel unprepared and lacking in knowledge and education 
necessary to engage in informed discussions with patients. Needs assessment surveys 
have been used, mostly among physicians, to identify and rank the most common factors 
involved in decision making about using cannabis for therapeutic purposes (Ziemianski et 
al., 2015). Canada’s national program for access to medical cannabis began in 2001; 
however, changes to the regulations which came into effect in August of 2016 allow 
nurse practitioners (NPs) to authorize eligible patients access to medical cannabis 
certification. This expansion in the NPs’ scope of practice prompted a national online 
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survey of NPs to assess knowledge and practice gaps related to medical cannabis, with 
the goal of informing the development of future education resources that increase clinical 
competence and improve patient care related to medical cannabis (Balneave, Alraja, 
Ziemianski, McCuaig & Ware, 2018). 
The national online survey of NPs was adapted from the national survey 
developed and used by Ziemianski et al. (2015). The survey consisted of six sections and 
assessed current and desired level of medical cannabis knowledge, desire for medical 
cannabis education, clinical experience related to medical cannabis, clinical barriers to 
prescribing and providing care related to medical cannabis, attitudes regarding which 
health care providers should be allowed to authorize medical cannabis use, and preferred 
formal for future medical cannabis education (Balneave et al., 2018; Ziemianski et al., 
2015). 
In 2013, there were 3,655 NPs eligible to practice in Canada. A convenience 
sample of 552 NPs were recruited through email lists of nursing organizations, of which 
227 accessed the national survey and 182  (33%) provided complete data for analysis. 
Descriptive statistics summarized respondents’ demographic information, knowledge, 
experiences, barriers, attitudes, and preference for educational approaches. Perceived 
knowledge gap was calculated by computing the difference between individuals’ current 
and desired knowledge level (i.e., only response pairs were used) (Balneave et al., 2018). 
Results of the study demonstrated that respondents were most knowledgeable 
about the potential uses (2.57/5.0) and risks (2.39/5.0) of medical cannabis as well as the 
safety, warning signs, and precautions associated with medical cannabis use (2.21/5.0). 
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The lowest mean knowledge level was for dosing and creating effective treatment plans 
(1.63/5.0), similarities and differences across cannabis products (1.83/5.0), and the 
current federal medical cannabis regulations (1.88/5.0) (Balneave et al., 2018). 
Similar gaps in perceived knowledge and perceived needs concerning medical 
cannabis have been identified by physicians, with the largest gaps between current and 
desired knowledge concerning dosing, the development of treatment plans, and 
comparisons between cannabis and existing prescription cannabinoids. There was an 
expressed need for better knowledge of the risks and benefits of medical cannabis, with 
respondents reporting that their comfort level in including medical cannabis in their 
practice would increase with added education focusing on literature reviews, online, and 
small group continuing medical education activities (Ziemianski et al., 2015). 
Cannabis education in APRN nursing programs. Although recommending 
medical cannabis is currently within the APRN scope of practice in US jurisdictions in 
which the use of cannabis is legal for medical purposes, the majority of patient 
certifications and recommendations have come from medical doctors (MD). Advanced 
Practice Registered Nurses remain responsible for maintaining or seeking knowledge and 
clinical competency related to patient care needs and clinical practice. Cannabis 
classification as a Schedule I controlled substance has limited research and empirical 
evidence supporting its effectiveness, and in turn medical and nursing education, has 
lacked instruction related to the pharmacology, physiologic effects, uses, neurological 
symptoms, drug-to-drug interactions, and adverse effects of cannabis. With the current 
and projected prevalence of cannabis use by patients, it is clear that the addition of 
curriculum content to provide APRNs with principles of safe and knowledgeable practice 
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is warranted. In order for APRNs to continue ensure safe and appropriate patient care, 
cannabis-specific curriculum content providing knowledge related to the current state of 
legalization for medical and recreational use, the endocannabinoid system, 
pharmacology, current research, and most importantly, safety considerations for the 
patient using cannabis is necessary (NCSBN, 2018). 
National Council of State Boards of Nursing (NCSBN) Guidelines. Sweeping 
changes in societal attitudes towards cannabis, and the increasing use and legalization of 
medical and recreational cannabis, prompted the National Council of State Boards of 
Nursing (NCSBN) in 2017 to appoint members to a NCSBN Marijuana Regulatory 
Guidelines Committee. Recognizing that nurses were unsure of their responsibilities in 
the care of patients who may use cannabis, the committee was charged with exploring the 
trends and issues related to cannabis use and nursing regulation in order to develop model 
guidelines for APRNs care of patients. Committee findings prompted recommendations 
for addition of curriculum content and the formation of model guidelines in the event 
APRNs are to be able to provide certification of a qualifying condition under state 
requirements (NCSBN, 2018). 
An in-depth review of current scientific literature also included the greater 
multitude of grey literature, or materials and research produced by organizations outside 
of traditional academic publishing and distribution channels. The committee consulted 
with known experts in the area of medical marijuana, its’ use, safety, and legislation. Pre-
licensure graduate-level education programs, as well as online educational content and 
other information available to nurses, was surveyed and found to be significantly lacking 
in providing knowledge for how to care for patients using cannabis (NCSBN, 2018). 
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The NCSBN review not only further highlighted the need for APRNs to have 
practical information to care for the increasing number of patients utilizing cannabis, it 
also established recommendations for APRN curriculum content as part of its national 
nursing guidelines for medical marijuana. Recommendations included the APRN student 
have a working knowledge of the current state of legalization, a working knowledge of 
the principles of an MMP, an understanding of the endocannabinoid system, cannabinoid 
receptors, cannabinoids, and the interactions between them, an understanding of cannabis 
pharmacology and the research associated with the medical use of cannabis, the ability  to 
recognize signs and symptoms of cannabis use disorder and cannabis withdrawal 
syndrome, the ability to  identify the safety considerations for patients using cannabis, 
and knowledge of administration and ethical considerations (NCSBN, 2018). 






The Logic Model, developed by the W.K. Kellogg Foundation (2004), is a 
beneficial tool that facilitates effective program planning, implementation, and 
evaluation. A Logic Model is a systematic and visual way to develop a clear program 
strategy based on the program’s desired results. A shared understanding of program 
goals, activities, and intended outcomes is necessary to engage others and clearly relay 
how a program will solve a particular problem.  
The overarching purpose of the Logic Model is to serve as a visual road map, 
connecting the purpose of the planned program with the program’s desired results. The 
Logic Model serves as a program design and planning tool to better organize program 
concepts, relationships, and structure. At the program implementation level, the Logic 
Model helps identify and collect data needed for ongoing monitoring and improvement, 
and as the model pictorially presents the components of the program, it clearly informs 
progress towards goals and program evaluation (Schmitz & Parsons, 1999; W.K. 
Kellogg, 2004). 
The Basic Logic Model (Figure 1) includes five components: resources; program 
activities; outputs; outcomes; and impact. Resources include the human, financial, 
organizational, and community resources a program has available to accomplish the 
activities. The program activities are processes, tools, events, actions, and interventions 
used to address the problem the program seeks to change. Outputs are the direct products 
of the program activities, or the evidence that the program has been delivered. Outcomes 
can be both short and long-term and include specific changes expected at the individual 
or program participant level resulting from the program, while impact is the long-term 
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intended or unintended change occurring at the organizational, community, or systems 
level as a result of the program. (Shakman & Rodriguez, 2015; W.K. Kellogg, 2004) 
 
Figure 1. The Basic Logic Model 










The purpose of the project was to evaluate the impact of a teaching module 
intended to provide essential knowledge and clinical implications of medical cannabis for 
the APRN student.  
Design 
This program development project included a pre-test, intervention, post-test 
design. The pre-test, or pre-video survey, was used to determine perceived current level 
of knowledge of medical cannabis among APRN student participants.  The intervention, 
an educational video was developed to educate APRN students on essential knowledge 
for medical cannabis. A post-video survey was administered after student completion of 
the educational video to measure improved knowledge.  
Sample and Site 
Advanced practice registered nurse students at Rhode Island College, School of 
Nursing (RIC SON), enrolled in Fall 2019 and Spring 2020 Nursing 505 Advanced 
Pharmacology, as well as Spring 2020 Nursing 620 were asked to participate in the study. 
The IRB approved informational letter, pre-video survey, and post-video survey were 
handed out prior to the start of class and the link to the educational video to be found 
online was given to students. The educational video consisted of a narrated PowerPoint 
presentation uploaded to YouTube.  
The Logic Model Framework 
 Resources/Inputs. Collaboration with Nursing 505 and 620 faculty confirmed the 
absence of medical cannabis knowledge within the current curriculum. Advanced 
practice registered nurse students enrolled in Nursing 505 and 620 were the targeted 
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group receiving the educational video. The program developer collaborated with course 
faculty to integrate the video into course curriculum. Clinical guidelines from the 
National Council of State Boards of Nursing (NCSBN) National Nursing Guidelines for 
Medical Marijuana (2018) were used to guide the content of the educational video. The 
program developer collaborated with APRNs from the NCSBN Regulatory Implications 
of Legal Cannabis Committee, who developed the guidelines, to review program content 
and assist as experts on this topic. 
 Activities/Procedures. The project proposal was accepted by the RIC IRB for 
review. The program developer completed the educational video. In collaboration with 
NURS 505 and 620 faculty, a date was selected for introduction of the study immediately 
before class. The program developer discussed the purpose of the study--to provide the 
APRN student with essential knowledge and clinical implications related to medical 
cannabis--and intended goals were discussed. Students were informed that the 
educational video was a required assignment, however completion of the pre- and post-
video survey was voluntary and anonymous. The educational video was a 30-minute 
narrated PowerPoint presentation which students were given the link to access online. A 
numbered pre- and post-video survey packet was handed out to students in class. The 
IRB approved informational letter explaining the purpose of the study as well as 
instructions for completing the pre-video survey followed by viewing the educational 
video, and the completing the post-video survey was also within this packet. Dates for 
completion of the pre-video survey, educational video, and post-video survey were 
assigned. Students were given two weeks to return the pre-video survey, two weeks to 
view the educational video, and two weeks to return the post-video survey. An email was 
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sent to all enrolled students three days prior to classes when surveys were due reminding 
them to bring their returned survey to class. An email was sent reminding them to view 
the educational video three days before the due date. Surveys were anonymous and 
results confidential. Completed survey packets were returned by students immediately 
before class or during class break to a manila folder and the program developer was 
available to pick the folder up following class the two weeks the pre- and post-video 
surveys were due.  
 Activities/Program Development. An educational video geared toward APRN 
students based on recommended essential knowledge for medical cannabis (NCSBN, 
2018) was developed. Content included: overview of current state of legalization of 
medical and recreational cannabis; principles of a medical marijuana program (MMP); 
endocannabinoid system; cannabis pharmacology and the research associated with the 
medical use of cannabis; signs and symptoms of cannabis use disorder and cannabis 
withdrawal syndrome; and safety considerations for patient use of cannabis. Content was 
generated directly from NCSBN guidelines described in Table 1. Prior to 
implementation, the program developer submitted the presentation to NCSBN advanced 










Essential Knowledge Elements of APRN Student Educational Module 
Purpose of Educational Module and 
NCSBN Guidelines 
 
Definitions Cannabis; Cannabidiol (CBD); 
Cannabinoid; Tetrahydrocannabinol 
(THC); Medical Marijuana Program 
(MMP) 
Current State of Legalization DEA; Schedule I Controlled Substance 
categorization, MMPs 
Principles of an MMP Department of Health statues; Health 
care provider responsibilities; Certifying; 
Qualifying conditions; APRN role 
The Endocannabinoid System (ECS) Discovery of ECS; Overview; Purpose; 
Cannabinoid receptors; Enzymes; THC, 
CBD, and CBN 
Cannabis Pharmacology and Research Current scientific evidence; Levels of 
evidence; Indications supported by 
evidence; Adverse effects; Routes of 
administration; Risks to particular groups 
of patients 
Clinical Encounter Considerations Signs and symptoms of cannabis adverse 
effects; Identification of safety 
considerations; Cannabis Use Disorder 
(CUD) 
Medical Cannabis Administration 
Considerations 
Hospitalized patient considerations; 
FDA-approved synthetic THC 
medications; Providers as MMP-
designated caregivers 
Ethical Considerations Patient care without judgement 
 
The educational video was tailored to meet the scheduling needs of both the 
students and the course, and included a 30-minute, narrated PowerPoint presentation that 
students had two weeks to complete. For ease of access, the educational video was 
uploaded to YouTube and the students were given the link to view the video. As a course 
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assignment, the educational video did not interfere with the current course curriculum or 
in-class time.    
 Outputs/Measurement. The goal was to have all APRN students enrolled in Fall 
2019 Nurs 505, Spring 2020 Nurs 505, and Spring 2020 Nurs 620 complete the 
educational video as well as the pre- and post-video survey. The pre- and post-video 
surveys were identical and consisted of nine knowledge items (see Appendix A). The 
concept of the knowledge survey was taken from a national needs-based survey 
developed and piloted by Canadian researchers Ziemianski et al. (2015). The entire 
survey by Ziemianski et al. consisted of six sections-- knowledge, experience, barriers, 
attitudes, educational opportunities, and demographics--with varying numbers of items. 
For the purpose of this study, the pre- and post-video survey only consisted of a 
knowledge section.  
The nine knowledge items from Ziemianski et al.’s survey prompted respondents 
to rank their perceived current level of knowledge on nine medical marijuana-related 
topics (see Table 2) using a 5-point Likert scale (1: very poor; 2: somewhat poor; 3: 
undecided; 4: somewhat good; and 5: very good). The nine items were utilized to identify 
Canadian physician’s perceived knowledge gaps and perceived needs concerning 
cannabis for therapeutic purposes. The concept of Ziemianski, et al.’s survey was 
combined with NCSBN (2018) recommended essential knowledge elements for medical 
marijuana education in APRN nursing programs found in Table 1. Knowledge areas 






Knowledge Areas Evaluated 
Knowledge area 
Current state of legalization of medical and recreational cannabis use. 
Principles of a Medical Marijuana Program (MMP). 
The endocannabinoid system, cannabinoid receptors, cannabinoids, and the 
interactions between them. 
Cannabis pharmacology and research associated with the medical use of cannabis. 
Signs and symptoms of cannabis use disorder and cannabis withdrawal syndrome. 
Safety considerations for patient use of cannabis. 
Medical marijuana administration considerations. 
Ethical considerations related to the care of a patient using medical marijuana. 
APRN role regarding certifying a qualifying condition. 
 
The effectiveness of the educational video was evaluated by the nine-item post-
video survey which was identical to the pre-video survey (see Appendix A) with the 
addition of a question which asked students if they completed the online educational 
video. Participants rated their perceived current level of knowledge for each of the nine 
items using the same Likert scale as Ziemianski et al. (1: very poor; 2: somewhat poor; 3: 
undecided; 4: somewhat good; and 5: very good). 
Additionally, both pre- and post-video surveys included a question which asked 
respondents to rate their perceived level of importance of integrating education on 
cannabis into the APRN curriculum. They rated their perceived level of importance using 
a 5-point-Likert scale (1: not at all important; 2: slightly important; 3: neutral; 4: 
moderately important; 5: extremely important). The mean perceived level of importance 
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was calculated for all pre-video survey responses, calculated for all post-video survey 
responses, and the difference between the post-video and pre-video means was 
calculated. 
Outcomes 
The short-term outcome of the educational video was to increase APRN student 
essential knowledge on medical cannabis and provide them with the NCSBN 
recommended essential knowledge elements for medical marijuana education in APRN 
nursing programs. Though beyond the scope of this project, the long-term goal is to 
incorporate the NCSBN recommended essential knowledge content into all accredited 
APRN education programs. Providing APRN students with principles to guide safe and 
knowledgeable practice will promote patient safety when caring for patients using 
cannabis. 
Data Analysis 
 Descriptive statistics summarize respondents’ knowledge ratings. Data were 
entered and analyzed using Microsoft Excel. Perceived current level of knowledge pre-
video was calculated by computing the mean respondent score for each item. The mean 
perceived level of knowledge post-video score was also calculated for each of the nine 
items. The increase in perceived level of knowledge was calculated by finding the 
difference between the mean response score for each of the nine pre-video survey 
questions and the mean response score for all post-video survey questions. Change in 
perceived level of importance with regard to integrating education on cannabis into the 
APRN curriculum was calculated by computing the difference in between the mean score 
for this item on pre-video and post-video surveys. 
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Data were analyzed for the survey question which asked respondents to rate their 
perceived level of importance of integrating education on cannabis into the APRN 
curriculum. Based on their perceived level of importance rating, the mean perceived level 
of importance was calculated for all pre-video survey responses, calculated for all post-
video survey responses, and the difference between the post-video and pre-video means 
was calculated. 








Participants in this study included Rhode Island College graduate nursing students 
enrolled in Advanced Pharmacology, Nurs 505, in the Fall of 2019 or Spring of 2020, as 
well as those graduate students enrolled in Nurs 620 during Spring of 2020. A total of 24 
students completed the pre-video survey and a total of 19 students completed the post-
video survey. 
Perceived Level of Knowledge Before Educational Video 
 Table 3 illustrates the analysis of study participants’ perceived level of knowledge 
on the nine knowledge area questions on the pre-video survey. The mean of all 
participant pre-video scores for all nine areas are presented.  
Table 3 
Analysis of Perceived Level of Knowledge Before Educational Module 
 
 
Knowledge items      Mean knowledge score 
(1-5) 
1 - Current state of legalization of medical and    2.96 
      recreational cannabis use. 
2 - Principles of a Medical Marijuana Program (MMP).   1.96 
3 - The endocannabinoid system, cannabinoid receptors,   1.92 
      cannabinoids, and the interactions between them. 
4 - Cannabis pharmacology and research associated with   2.04 
      the medical use of cannabis. 
5 - Signs and symptoms of cannabis use disorder and   2.54 
     cannabis withdrawal syndromes. 
6 - Safety considerations for patient use of cannabis.   2.67 
7 - Medical marijuana administration considerations.   2.54 
8 - Ethical considerations related to the care of a patient   2.67 
     using medical marijuana. 




Mean knowledge scores ranged from 1.83/5.0 to 2.96/5.0. Prior to watching the 
educational video, respondents perceived that they were most knowledgeable about 
current state of legalization (2.96/5.0), safety considerations (2.67/5.0), ethical 
considerations (2.67/5.0), signs and symptoms of cannabis use disorder and cannabis 
withdrawal (2.54/5.0), and administration considerations (2.54/5.0). In contrast, the 
lowest mean perceived level of knowledge was for the APRN role (1.83/5.0), the 
endocannabinoid system (1.92/5.0), principles of a Medical Marijuana Program 
(1.96/5.0), and cannabis pharmacology (2.04/5.0). 
Perceived Level of Knowledge Post Educational Video 
 Table 4 illustrates the analysis of study participants’ perceived level of knowledge 
on the nine knowledge area questions on the post-video survey. The mean of all 




















The mean score on all post-video survey knowledge items ranged from 4.42/5.0 to 
4.79/5.0. Following the educational video, respondents perceived that they had a greater 
than “somewhat good” level of knowledge on all knowledge items. They had the highest 
perceived knowledge on signs and symptoms of cannabis use disorder and cannabis 
withdrawal syndromes (4.79/5.0), safety considerations for patient use of cannabis 




Knowledge items      Mean knowledge score (1-5) 
1 - Current state of legalization of medical and    4.63 
      recreational cannabis use. 
2 - Principles of a Medical Marijuana Program (MMP).   4.53 
3 - The endocannabinoid system, cannabinoid receptors,   4.58 
      cannabinoids, and the interactions between them. 
4 - Cannabis pharmacology and research associated with   4.42 
      the medical use of cannabis. 
5 - Signs and symptoms of cannabis use disorder and   4.79 
      cannabis withdrawal syndromes. 
6 - Safety considerations for patient use of cannabis.   4.74 
7 - Medical marijuana administration considerations.   4.74 
8 - Ethical considerations related to the care of a patient   4.63 
     using medical marijuana. 




Table 5 illustrates the analysis of the increase in study participants’ perceived 
level of knowledge following the educational video.  
Table 5 
Analysis of Difference in Perceived Level of Knowledge Pre- and Post-Educational 
Module 
 
The survey knowledge items with the greatest increase in perceived level of 
knowledge (i.e., perceived level of knowledge post-video – perceived level of knowledge 
pre-video) following the educational video were as follows: the endocannabinoid system; 
cannabinoid receptors; cannabinoids; and the interactions between them, the APRN role 
regarding certifying a qualifying condition; and principles of a Medical Marijuana 
Program. While the mean perceived level of knowledge on pre-video knowledge items 
ranged from 1.83–2.96/5.0, the mean on all post-video knowledge items ranged from 
4.44–4.79/5.0.  
Knowledge items  Change in knowledge 
            score (1-5) 
1 - Current state of legalization of medical and    +1.67 
      recreational cannabis use. 
2 - Principles of a Medical Marijuana Program (MMP).   +2.57 
3 - The endocannabinoid system, cannabinoid receptors,   +2.66 
      cannabinoids, and the interactions between them. 
4 - Cannabis pharmacology and research associated with   +2.38 
      the medical use of cannabis. 
5 - Signs and symptoms of cannabis use disorder and   +2.25 
      cannabis withdrawal syndromes. 
6 - Safety considerations for patient use of cannabis.   +2.07 
7 - Medical marijuana administration considerations.   +2.20 
8 - Ethical considerations related to the care of a patient   +1.96 
      using medical marijuana. 




Importance of Cannabis Education 
 Table 6 illustrates the analysis of study participants’ perceived level of 
importance with regard to integrating education on cannabis into the APRN curriculum. 
Table 6 
 
Analysis of Difference in Perceived Level of Importance of Education on Cannabis in  
APRN Curriculum 
 
The mean score for the perceived importance of integrating cannabis education 
into the APRN curriculum increased from 4.45/5.0 on pre-video surveys to 4.77/5.0 on 
post-video surveys. 










       Mean score (1-5) 
 
Pre-Video Survey       4.45 
 





Summary and Conclusions 
 As interest in medical cannabis continues to grow in the United States, healthcare 
providers, including APRNs, will be faced with increasing requests for information and 
guidance from patients regarding the use of medical cannabis for health-related issues. 
With federal regulations allowing APRNs to certify a qualifying condition, APRNs may 
also become a major source of education, decision support, and access for patients. 
Literature has examined the knowledge and practice gaps related to medical cannabis in a 
national sample of Canadian physicians and nurse practitioners and the findings have 
demonstrated a strong need for education on all aspects of cannabis (Balneaves et al., 
2018; Ziemianski et al., 2015).  
 The NCSBN study (2018) results informed specific guidelines: nursing care of the 
patient using medical marijuana; medical marijuana education in pre-licensure nursing 
programs; medical marijuana education in APRN nursing programs; and APRNs 
certifying a medical marijuana qualifying condition. The Logic Model (2004) was used 
as a framework to effectively plan the and incorporate the NCSBN guidelines into an 
effective educational module, implement the intervention, and evaluate the outcome of 
the project.  
The purpose of the project focused on evaluating the impact of the educational 
module designed to provide the NCSBN essential knowledge elements of medical 
cannabis to the APRN student. The educational module was a 30-minute narrated 
PowerPoint presentation which students viewed at home as part of their course 
curriculum. A pre-video survey was used to determine perceived current level of 
knowledge of medical cannabis among APRN student participants prior to watching the 
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educational video and a post-video survey was administered after student completion of 
the video to measure improved knowledge.  
Descriptive statistics summarized respondents’ knowledge ratings on both pre- 
and post-video surveys. The change in perceived level of knowledge following the 
educational video was calculated by finding the difference between the mean response 
score for each of the nine pre-video survey questions and the mean response score for all 
post-video survey questions. An additional survey question asked respondents to rate 
their perceived level of importance with regard to integrating education on cannabis into 
the APRN curriculum. The change in response following the educational module for this 
question was also calculated by computing the difference in the mean score for this item 
on pre-video and post-video surveys. 
When using the NCSBN guidelines for medical marijuana education in APRN 
nursing programs, and the nine essential knowledge recommendations, this project 
demonstrated that, at baseline APRN students’ perceived level of knowledge for all 
knowledge items was between very poor and neutral. If the knowledge items represent 
essential knowledge necessary to provide safe patient care to patients using medical or 
recreational cannabis, this low level of perceived knowledge is concerning. This low 
level of perceived knowledge also supports the integration of these essential knowledge 
recommendations into APRN curriculum in order to best care for the increasing number 
of patients using cannabis. 
 The largest knowledge gaps identified were related to background knowledge of 
cannabis, the endocannabinoid system, cannabis pharmacology, and the APRN role in 
certifying a qualifying condition. This knowledge could easily be integrated into the 
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theory component of upper level course curriculum. Advanced practice registered nurse 
students perceived their knowledge of the more clinical elements better but still 
somewhat poor. These knowledge elements, such as signs and symptoms of cannabis use 
disorder and cannabis withdrawal syndrome, safety considerations, administration 
considerations, and ethical considerations could most likely be incorporated into the 
clinical competency portion of the curriculum.  Students could be encouraged to address 
these elements with at least one patient over the course of their 600-direct-patient-care-
hour requirement. 
 Another option for increasing APRN students’ perceived level of knowledge 
related to cannabis would be the integration of an educational video module similar to the 
one developed for this study. The video module provided the APRN student with 
pertinent information related to each of the nine essential knowledge elements outlined 
by the NCSBN study. Following the video, APRN students perceived knowledge was at 
least “somewhat good”, if not “very good” on all nine items. Furthermore, prior to the 
educational video, students rated their perceived level of knowledge as “somewhat good” 
or “very good” only 22% of the time compared to 99% of the time after watching the 
video. If  “somewhat good” or “very good” perceived level of knowledge is identified as 
the goal which curriculum should meet, the educational video intervention met the goal 
of increasing student perceived level of knowledge to an adequate level. Students 
perceived that their level of knowledge increased the most in the knowledge items related 
to principles of a Medical Marijuana Program, the endocannabinoid system, and the 
APRN role regarding certifying a qualifying condition. 
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 The APRN student respondents perceived the importance of integrating education 
on cannabis into the APRN curriculum as moderately and extremely important both 
before and after watching the educational video. This perceived level of importance 
suggests that students believe that knowledge related to cannabis is, and/or will be, 
essential to their role as an APRN. Students expect that curriculum is preparing them 
with the knowledge necessary to fulfill the APRN role and provide appropriate and safe 
patient care. Thus, APRN student perception that integration of cannabis education into 
the APRN curriculum is moderately to extremely important may support funding for a 
gap analysis and proposed areas of integration into current course curriculum. 
 Limitations to these findings must be noted such as the small sample size, which 
represented only a small percentage of APRN students. As a convenience sample, APRN 
students who participated in the study may have held a unique perspective or interest in 
medical cannabis not representative of the larger APRN student or APRN community. 
Also, due to the fact that watching the educational video was an ungraded course 
assignment, there was no way to confirm whether all participants completing post-video 
surveys had completed the educational module.  
             In summary, given the limited amount of knowledge related to medical cannabis 
in the current APRN curriculum together with the increasing prevalence of its use, the 
findings remain relevant and will inform future education programming. 





Recommendations and Implications for Advanced Nursing Practice 
 As the demand for medical cannabis increases and the prevalence of patients 
using cannabis for medical purposes continues to rise, education within APRN programs, 
as well as continuing education for those in practice, is urgently needed to ensure safe 
patient care. The NCSBN National Nursing Guidelines for Medical Marijuana Education 
in APRN Nursing Programs, which outlines nine essential knowledge principles 
necessary for APRN students, should be reviewed and incorporated into accredited 
APRN course curriculum. Accredited programs should perform a gap analysis in order to 
identify existing content and course objectives, as well as to identify the most appropriate 
content areas to integrate the recommended knowledge principles. 
 Advanced practice registered nursing education should include essential  
knowledge such as: the current state of legalization of medical and recreational cannabis 
use; principles of an MMP; the endocannabinoid system, cannabinoid receptors, 
cannabinoids, and the interactions between them; cannabis pharmacology and the 
research associated with medical use of cannabis; signs and symptoms of cannabis use 
disorder and cannabis withdrawal syndrome; safety considerations for patient use of 
cannabis, medical marijuana administration considerations; ethical considerations related 
to the care of a patient using medical marijuana; and the need to follow specific employer 
policies and procedures, standard of care arrangements, and facility policy and 
procedures regarding certifying a qualifying condition. 
 Integration of essential medical cannabis knowledge into APRN education can be 
accomplished by following the NCSBN National Nursing Guidelines for Medical 
Marijuana Education in APRN Nursing Programs and expanding various areas of 
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program curriculum. For example, essential cannabis knowledge could be integrated into 
advanced pharmacology course content through the development of a tailored online 
education program or educational video inclusive of all knowledge elements such as the 
video used in this project. Essential knowledge could be added to lecture material or 
assigned as additional course required material or reading. Online continuing professional 
development and in-person seminars, fulfilling student conference hour requirements, is 
another educational strategy option. 
 Additionally, there is an ongoing need for clinical evidence-based research on the 
use of cannabis for medical purposes. A more robust body of literature will best inform 
clinical practice guidelines and support all healthcare practitioners in providing effective 
and safe patient care. More information regarding student APRN and licensed APRN 
knowledge, attitudes, and beliefs surrounding medical cannabis is necessary to inform the 
most effective educational strategies for integrating knowledge into curriculum and 
continuing education.  
 As the APRN scope of practice authorizes certification of a qualifying condition, 
APRNs need to be supported and provided education appropriate to fulfill this role and 
provide safe patient care. As state legislative bodies create MMP requirements, policy 
should ensure a minimum educational requirement for medical cannabis be met by 
certifying practitioners. Similar to the mandatory opioid/pain management CEUs many 
states have adopted, states with MMPs should mandate medical cannabis CEUs to ensure 
providers have a basic knowledge necessary to appropriately care for this expanding 
patient population. In the meantime, nursing regulatory organizations, government 
agencies, and academic institutions must work collaboratively to identify knowledge 
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gaps, tailor educational programs, and outline clinical competencies specific to medical 
cannabis knowledge clinicians will use in practice.  
 In summary, recommending medical cannabis and certifying a medical marijuana 
qualifying condition is within the APRN scope of practice within US jurisdictions which 
have legalized cannabis for medical use. As licensed healthcare providers, APRNs are 
responsible for maintaining or seeking knowledge and clinical competency related to 
patient-care needs and clinical practice. In order to ensure safe and appropriate patient 
care, APRN programs must stay up-to-date on matters of common interest and concern 
affecting the public health, safety, and welfare. Educational programs must also ensure 
curriculum supports the development of knowledge applicable to licensing examinations 
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1) Please rank your perceived current level of knowledge on the nine (9) cannabis-related 
topics below.  
 
  5 = very good         4 = somewhat good         3 = undecided         2 = somewhat poor         1 = very poor 
 
2) In terms of integrating education on cannabis into the APRN curriculum, please circle 
your perceived level of importance. 
 
5 = Extremely important  
4 = Moderately important 
3 = Neutral 
2 = Slightly important 
1 = Not at all important 
Knowledge area  
1 - Current state of legalization of medical and recreational 
cannabis use. 
     5      4      3      2      1 
2 - Principles of a Medical Marijuana Program (MMP)      5      4      3      2      1 
3 - The endocannabinoid system, cannabinoid receptors, 
cannabinoids, and the interactions between them. 
     5      4      3      2      1 
4 - Cannabis pharmacology and research associated with the 
medical use of cannabis. 
     5      4      3      2      1 
5 - Signs and symptoms of cannabis use disorder and cannabis 
withdrawal syndrome. 
     5      4      3      2      1 
6 - Safety considerations for patient use of cannabis.      5      4      3      2      1 
7 - Medical marijuana administration considerations.      5      4      3      2      1 
8 - Ethical considerations related to the care of a patient using 
medical marijuana. 
     5      4      3      2      1 
9 - APRN role regarding certifying a qualifying condition.      5      4      3      2      1 
